eligibility_summary
Eligible: ≥18 with untreated biopsy-confirmed CD20+ monomorphic PTLD/immunodeficiency lymphoma post solid organ or HSCT, ECOG ≤3, labs: ANC ≥1.0K, Plt ≥75K, Hgb ≥8, bili <1.5×ULN, AST/ALT <2.5×ULN, CrCl >30. If marrow involvement: ANC ≥0.5K, Plt ≥50K, Hgb ≥7. Contraception/consent required. Exclude: CNS disease, neuropathy ≥2, EF<40%, uncontrolled illness/infection, recent investigational drugs, severe allergy, pregnant/breastfeeding, active HBV/HCV. HIV allowed if on ART, stable, CD4>250, VL<200. Some prior cancers allowed. Investigator discretion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I/II trial in CD20+ post-transplant lymphoproliferative disorder (PTLD) testing polatuzumab vedotin (Pola) + rituximab as frontline, patients lacking interim complete response add CHP (cyclophosphamide, doxorubicin, prednisone). Polatuzumab vedotin: antibody-drug conjugate targeting CD79b on B cells, delivering MMAE (microtubule inhibitor) to induce apoptosis. Rituximab: chimeric anti-CD20 monoclonal antibody depleting B cells via CDC, ADCC, and apoptosis. CHP adds cytotoxic chemotherapy and steroid: cyclophosphamide (alkylator), doxorubicin (anthracycline/topo II inhibitor/DNA intercalator), prednisone (glucocorticoid, lympholytic). Targets/pathways: malignant B cells (CD79b, CD20), microtubules, DNA/topo II, glucocorticoid receptor, leverages innate effector mechanisms (ADCC/CDC).